Autologous CRISPR-Cas9 Engineered Tumor Infiltrating Lymphocytes KSQ-001EX

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous tumor infiltrating lymphocytes (TILs) gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to inactivate the endogenous gene suppressor of cytokine signaling 1 (SOCS1), with potential immunomodulating and antineoplastic activities. Upon infusion of the autologous CRISPR-Cas9 engineered TILs KSQ-001EX back into the patient, the cells specifically recognize, target and kill the patient's tumor cells. SOCS1 serves as a negative regulator of cytokine signaling in T-cells and negatively influences the survival, differentiation, and function of T-cells. Inactivation of endogenous SOCS1 in TILs increases responsiveness to cytokine signals, and enhances anti-tumor potency, persistence and memory formation of TILs.

**Synonyms:** - Autologous CRISPR-Cas9 Engineered TILs KSQ-001EX - Autologous Engineered Tumor Infiltrating Lymphocytes KSQ-001EX - Autologous SOCS1 Inactivated Engineered TILs KSQ-001EX - Autologous SOCS1-edited TILs KSQ-001EX - Autologous eTILs KSQ-001EX - CRISPR/Cas9-edited SOCS1 Gene-inactivated Autologous TILs KSQ-001EX - KSQ 001EX - KSQ-001EX - KSQ001EX